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Abstract
Lung cancer is the top cause of cancer-related deceases. One of the reasons is
the development of resistance to the chemotherapy treatment. In particular,
cancer stem cells (CSCs), can escape treatment and regenerate the bulk of the
tumor. In this article, we describe a comparison between cancer cells resistant
to cisplatin and CSCs, both derived from the non-small-cell lung cancer cell
lines H460 and A549. Cisplatin-resistant cells were obtained after a single treat-
ment with the drug. CSCs were isolated by culture in defined media, under
nonadherent conditions. The isolated CSCs were clonogenic, could be differen-
tiated into adherent cells and were less sensitive to cisplatin than the original
cells. Cisplatin resistant and CSCs were able to generate primary tumors and to
metastasize when injected into immunodeficient Nu/Nu mice, although they
formed smaller tumors with a larger latency than untreated cells. Notably,
under appropriated proportions, CSCs synergized with differentiated cells to
form larger tumors. CSCs also showed increased capacity to induce angiogene-
sis in Nu/Nu mice. Conversely, H460 cisplatin-resistant cells showed increased
tendency to develop bone metastasis. Gene expression analysis showed that sev-
eral genes involved in tumor development and metastasis (EGR1, COX2,
MALAT1, AKAP12, ADM) were similarly induced in CSC and cisplatin-resis-
tant H460 cells, in agreement with a close similarity between these two cell
populations. Cells with the characteristic growth properties of CSCs were also
isolated from surgical samples of 18 out of 44 lung cancer patients. A signifi-
cant correlation (P = 0.028) was found between the absence of CSCs and cis-
platin sensitivity.
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Introduction
Lung cancer represents a life-threatening disease that pro-
duced 22.3% of the cancer-related deceases in men and
11.3% in women worldwide in 2008 [1]. Besides its high
incidence, mortality is increased by the frequent develop-
ment of resistance to the drugs used in the treatment.
Relapses often appear after surgical or pharmacological
treatment that are more resistant to chemotherapy than
the original tumor [2]. Therefore, a large effort is being
devoted to the study of lung cancer, its development and
the acquisition of drug resistance.
One model that has received considerable attention in
last years explains the existence of relapses and the acqui-
sition of resistance to chemotherapy by the existence of
Cancer Initiating Cells, also designed as cancer stem cells
(CSCs) [3]. According to this model, a proportion of the
tumor cells are initiating cells that divide asymmetrically
to generate a new stem cell and a daughter cell that dif-
ferentiates and also continues proliferating to contribute
to the main mass of the tumor. Stem cells would be more
resistant to chemotherapy and would more probably
overcome tumor treatment. Therefore, remaining stem
cells would be able to regenerate the tumor, producing
relapses that could acquire increased resistance to the
drug used for primary tumor treatment.
Cancer stem cells have been identified in different
tumors. Their identification can be based on the expres-
sion of specific markers, on the capacity of these cells to
secrete fluorescent molecules or on their capacity to grow
in defined media under nonadherent conditions. The
more frequent type of lung cancer (85% of the cases) is
non-small-cell lung cancer (NSCLC). Several articles have
reported the isolation of CSC from NSCLC cell lines
(reviewed in [4, 5]). In most of these studies the expres-
sion of different stem cells markers or fluorescent dyes
exclusion criteria were used for isolation of the stem
cells.
Drug resistance has also been studied in NSCLC cells.
One of the chemotherapeutic drugs more extensively used
for NSCLC treatment is cisplatin and several authors,
including ourselves [6], have studied cisplatin resistance
in lung cancer. Among the mechanisms described are
alterations of intracellular signaling pathways, changes in
RNA expression or epigenetic mechanisms (for recent
reviews [7, 8]).
In this article, we have approached the possible rela-
tionship between induced cisplatin resistance and the
stem properties of NSCLC cells. Cancer stem cells were
isolated because of their capacity to grow in a defined
culture media, under nonadherent conditions. On the
other hand, cisplatin-resistant cells were obtained after a
single treatment with cisplatin, in an attempt to repro-
duce the protocols used for patient chemotherapy. Both
cell populations have been compared in terms of cisplatin
sensitivity, tumorigenicity, metastatic capacity, and gene
expression profiles and several similarities have come out,
in agreement with the CSC model.
Materials and Methods
Cell culture, transfection, and selection of
cisplatin resistant and CSC populations
Human NSCLC H460 and A549 cells, purchased from the
American Type Culture Collection were cultured in RPMI
(Roswell Park Memorial Institute, Gibco, Carlsbad, CA)
media supplemented with 10% foetal bovine serum (FBS).
Cisplatin-resistant cells were obtained after treatment of
H460 or A549 cells with 0.5 lg/mL (1.7 lmol/L) or
2.5 lg/mL (8.3 lmol/L) of cisplatin, respectively, for 72 h.
After this treatment, cells were cultured in the absence of
the drug. Cancer stem cell populations were isolated by
culture in DMEM (Dulbeco modified eagle medium)/F12
(Gibco, Carlsbad, CA) (1:1) media supplemented with
2 mmol/L-Glutamine, 5 mmol/L Hepes, 0.4% BSA (bovine
serum albumin), N2 supplement (Gibco, Carlsbad, CA)
and 20 ng/mL of epidermal growth factor and bFGF (basic
fibroblast growth factor) (PeproTech, Rocky Hill, NJ).
Cells were transfected with the plasmid pmCherry-N1
using Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA) and selected by their resistance to neomycin
(G418). Green-Fluorescent protein (GFP)-expressing cells
were obtained by infection with the pGIPZ-shRNAmir-NS
lentiviral vector (Open Biosystems, Thermo Scientific,
Madrid, Spain).
Cell-viability assays
Cells were cultured in 96-well plates at a density of 50
cells/well for 24 h, cisplatin was added and the culture
continued for 72 additional hours. The number of viable
cells was estimated using the MTS ([3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) hydrolysis method (Promega Corpora-
tion, Madison, WI).
Clonogenicity assays
The capacity of the cells to grow as clones derived from
single cells was assayed by soft-agar culture, as described
[9]. Clonogenicity was also tested in liquid culture by
seeding individual cells in 96-wells plates under adherent
and nonadherent culture conditions.
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In vitro cell invasion assays
104 cells were seeded in the upper part of BD BioCoatTM
MatrigelTM invasion chambers (BD Biosciences, San Jose,
CA) in medium containing 0.5% FBS, 0.1% BSA. In the
case of CSCs, defined media containing 0.1% BSA and
without growth factors was used. Culture medium con-
taining 10% FBS was added to the lower part of the
chambers. Cells that had invaded the matrigel layer after
24 h of culture were stained using the Diff Quick method
(Medion Diagnostics, Duedingen, Switzerland) and quan-
tified using the analySIS program (Soft Imaging System
Olympus, Tokyo, Japan).
Tumorigenicity in xenograft mouse models
Matrigel (BD Biosciences)-impregnated cells were injected
in both flanks of athymic Foxn1nu female mice. Tumor
volume was calculated as l 9 w2 9 0.52, being l the
length and w the width of the tumors. In cell-mixture
experiments, cells expressing the GFP or the Cherry pro-
teins were mixed before injection into mice. Mice were
sacrificed 30 days later tumors were removed, fixed in
formaldehyde, included in OCT (Optimal Cutting tem-
perature), and cut in 10 lm sections. The percentage of
GFP and Cherry-expressing cells was determined using
the ImageJ program (National Institutes of Health,
Bethesda, MD).
In vivo angiogenesis assays
Athymic female mice were subcutaneously injected with
300 lL of Matrigel containing 30 lg of conditioned
media. bFGF and PBS (phosphate buffered saline) were
used as positive and negative controls, respectively. Mice
were sacrificed 10 days after injection, plugs were
removed and the presence of microvessels assayed by
CD31 expression as previously described [10].
Metastasis assays
Nude mice of 6 weeks were injected in the tail with 106
cells suspended in 100 lL of physiologic serum. After ani-
mal’s death, a complete necropsy examination was per-
formed [11]. The brain, salivary glands, and visceral
organs were fixed in 4% formaldehyde, embedded in par-
affin and cut in 5 lm sections that were stained with
Hematoxylin and Eosin. To study bone metastasis, femurs
were fixed with 4% formaldehyde for 24 h and incubated
in 70% ethanol at 4°C before decalcification in 4% HCl,
4% formic acid for 5 days. Bones were then incubated in
70% ethanol and embedded in paraffin. Five lm sections
were obtained and stained with Hematoxylin and Eosin.
Gene expression analyses by microarray
hybridization
Total cellular RNA was isolated using the Trizol reagent
(Invitrogen, Carlsbad, CA) and purified with the RNeasy
Mini kit (Qiagen, Valencia, CA). Duplicate RNA samples
were converted to labeled cDNA using the Two-Color
Microarray-Based Gene Expression Analysis kit (Quick
Amp Labelling; Agilent Technologies, Santa Clara, CA).
Dye-swap labeled cDNAs were hybridized to Whole
Human Genome Microarrays 4x44K G4112F (Agilent) in
technical duplicates. Hybridized Microarrays were
scanned and the data extracted using the Feature Extrac-
tion Software (Agilent). Analysis of the data was per-
formed at the National Biotechnology Center (CNB,
Madrid, Spain). Differential expression comparisons were
made using the Rank Products method [12]. Data were
filtered and visualized using the FIESTA program [13].
Genes common in different comparisons were identified
and represented in a Venn diagram using the VENNY
program [14]. Functional enrichment of differentially
expressed genes was analyzed using the GOTree Machine
(GOTM) [15].
Quantitative RT-PCR analysis of gene
expression
cDNA was obtained from 1 lg of each RNA using the
High-Capacity cDNA Archive Kit (Applied Biosystems,
Madrid, Spain). Quantitative PCR analyses was carried out
in triplicate samples using TaqMan probes and the Taq-
man Universal PCR Master Mix (Applied Biosystems)
using a Step One Plus Real-Time PCR System (Applied
Biosystems). The following probes were used in these stud-
ies: Hs03929097_g1 (GAPDH), Hs99999903_m1 (b-actin),
Hs01555410_m1 (IL1B), Hs00158757_m1 (LOXL2), Hs025
62698_s1 (ADM), Hs00152928_m1 (EGR1), Hs019101
77_s1 (MALAT1), Hs00153133_m1 (COX2), Hs1103
582_s1 (JUN), Hs011112126_m1 (AKAP12), Hs0233006
9_s1 (CXCR4), Hs00610256_g1 (DUSP1), Hs00737962_m1
(DUSP6), Hs00153458_m1 (VEGFC), Hs03044178_g1
(CD24), Hs01053790_m1 (ABCG2). Relative gene expres-
sion quantification was calculated according to the com-
parative threshold cycle method [16] using b-actin or
GAPDH as endogenous controls.
Protein expression analysis
Cells extracts were obtained and analyzed as described
[17]. Primary antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz Biotech, Dallas, TX)
(Fibronectin), Cell Signaling (Cell Signalling Technology,
Danvers, MA) (E-Cadherin, Vimentin, ZO-1) or Sigma
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(St. Louis, MO) (a-tubulin). Secondary antibodies
were obtained from BioRad (Berkeley, CA) and Cell
Signaling.
Processing of surgical samples
Surgical samples of lung cancer were collected at the
Hospital Universitario La Paz, Madrid, Spain. Samples
were collected in DMEM/MixF12Ham (Sigma), digested
with Collagenase (0.3 mg/mL), and Hyaluronidase
(125 U/mL) (both from Sigma) for 20 min at 37°C,
mechanically disaggregated and filtered.
Results
Isolation of cisplatin-resistant NSCLC cells
H460 and A549 NSCLC cell lines were incubated with
a single dose of cisplatin, 0.5 lg/mL (1.7 lmol/L) for
H460 (determined IC50 = 0.3 lg/mL) and 2.5 lg/mL
(8.3 lmol/L) for A549 cells (determined
IC50 = 0.75 lg/mL). The possible induction of drug
resistance was analyzed after 3 days in drug-free culture
(R-3d), when treated cells reached confluence (21 days
for H460 R-21d, 15 days for A549 R-15d) and after
these cells were frozen and thaw out again into culture
(H460R-FT, A549R-FT). Cells that survived to a single
dose of cisplatin were less sensitive to this drug than
the original populations (Fig. 1). Sensitivity increased
from 3 to 15 or 21 days in culture in the absence of
drug and got stabilized for prolonged periods of culture
thereafter.
Isolation and characterization of CSCs from
NSCLC cell lines
H460 and A549 cells were cultured in defined, serum-free,
media under nonadherent conditions to detect the possi-
ble presence of cells with tumor initiating characteristics.
Cells from both cell lines were able to grow forming
spheroid aggregates (Fig. 2A). The clonogenic capacity
was analyzed by plating them in 96-Well plates. An aver-
age number of 48 cells were seeded on each plate under
adherent or nonadherent conditions. Figure 2B indicates
the total number of clones or spheres containing more
than four cells obtained. Spheres were originated from
individual cells that were considered CSCs.
The dependence of these cells on growth factors was
determined. The results obtained (Fig. S1A) indicate that
while A549 cells were dependent on the growth factors
added to the media, H460 cells grew in their absence.
Actually, conditioned media obtained from H460 cells
supported A549 spheres growth without additional
growth factors (Fig. S1A).
The expression of CSC markers was analyzed by quan-
titative reverse transcription-polymerase chain reaction
(RT-PCR, Fig. S1B). H460 CSCs showed increased expres-
sion of CD133 and decreased levels of CD44 and CD166.
In contrast, A549 CSCs showed increased levels of CD44
and decreased CD133 expression. H460 cisplatin-resistant
cells showed increased CD133 expression, as H460C cells.
A549 cisplatin-resistant cells showed increased CD44
expression, as A549C cells, but also increased CD133
expression (Fig. S1B). Both H460C and A549C cells
expressed lower levels of the CD24 and ABCG2 CSC
H460R-FT
A
A549R-FT
B
Figure 1. Cisplatin sensitivity of the NSCLC H460 and A549 cells after a single treatment with the drug. H460 and A549 cells were incubated
with 0.5 lg/mL (1.7 lmol/L) or 2.5 lg/mL (8.3 lmol/L) of cisplatin, respectively, for 3 days. The cells that survived the treatment, H460R (A) and
A549R (B), were assayed for cisplatin sensitivity either at the end of cisplatin treatment (H460R-3d, A549R-3d), at the time when treated cells
reached confluence (H460-21d, A549R-15d) or after these cells were frozen and thaw out back into culture (H460R-FT, A549R-FT). Cell viability
was determined using the MTS reagent. Average and Standard deviations of three independent experiments are shown.
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marker genes than untreated cells. H460R cells also
expressed lower levels of both genes while A549R cells
showed decreased CD24 and increased ABCG2 expression
(data not shown).
CSCs are supposedly more resistant to anticancer drugs
than the bulk of cells from the same tumor. The sensitiv-
ity to cisplatin of H460 and A549 CSCs was analyzed and
both CSCs were less sensitive to the drug than untreated
cells (Fig. 2C). Actually, previously isolated resistant cells
showed an intermediate behavior between CSCs and
untreated cells (Fig. 2C). CSCs isolated from H460-resis-
tant cells (H460R-C) showed a cisplatin sensitivity similar
to that of H460C cells (Fig. 2C).
CSCs might also have increased invasive capacity and
undergo Epithelial/Mesenchymal Transition (EMT). Both
characteristics were analyzed for H460 CSCs and cis-
platin-resistant cells. A significant increase in cell migra-
tion was observed for H460 cisplatin-resistant cells
(H460R) using an in vitro Matrigel invasion assay
(Fig. 2D). H460 CSCs also showed increased migration
although the difference with untreated H460 cells was not
statistically significant. However, CSCs migrated as cell
aggregates (Fig. 2D) which might result in an underesti-
mation of their migration capacity, determined as the sur-
face of the filter covered by migrating cells.
Epithelial/Mesenchymal Transition was determined by
studying the expression of epithelial and mesenchymal
markers. CSCs, cisplatin-resistant cells and CSCs that
were allowed to redifferentiate by culture in adherent
plates with standard culture media (dif CSC) were ana-
lyzed. H460 and A549 cells differed markedly in the
expression of epithelial and mesenchymal markers such as
E-Cadherin, Fibronectin, ZO-1 or Vimentin (Fig. S1C, see
expression ratios). However, both derived CSCs showed
similar response, the expression of epithelial markers
(E-cadherin, ZO-1) and one of the mesenchymal markers
(Fibronectin) increased while the other mesenchymal
marker (Vimentin) showed decreased expression. Differ-
entiation of H460 CSCs reverted these changes (Fig. S1C).
These results indicated a mixed epithelial/mesenchymal
phenotype in the CSCs.
Tumorigenic capacity of the H460 CSCs and
cisplatin-resistant cells
Different numbers of untreated, H460 resistant or H460
CSCs were injected subcutaneously in immunodeficient
mice. Latency and tumor size 30 days after cell injection
was determined (Table S1). CSCs and resistant cells
induced smaller tumors with a longer latency period, indi-
cating that they grew more slowly than the untreated H460
cells in the mouse xenografts. Since tumors are considered
a mixture of CSCs and differentiated cells, we analyzed the
behavior of mixed populations of both cell types. H460
cells expressing the Cherry-fluorescent protein were mixed
with CSCs expressing GFP to distinguish the cells of the
tumor coming from each population. Labeled H460 and
CSCs were mixed in different proportions before inocula-
tion. The latency period and tumor size at the end of the
experiment were determined (Table 1). Tumors were
resected and the proportion of red-H460 and green-CSCs
estimated. In three of the four cell mixtures tested, the pro-
portion of CSCs at the end of the experiment was smaller
than at the beginning, indicating slower growth, in agree-
ment with the results obtained injecting CSCs alone. How-
ever, when 25% of CSCs were present, their percentage
increased to 34.58% in the tumor. In addition, the tumors
obtained showed shorter latency and larger volume than
those obtained with other cell proportions. These data indi-
cate that some proportions of CSCs and differentiated cells
can potentiate the growth of both cell types, resulting in
more aggressive tumors.
The angiogenic potential of H460, CSCs, and cisplatin-
resistant cells was evaluated in vivo. Conditioned media
prepared from these cell lines was included in matrigel
plugs and implanted subcutaneously into flanks of nude
mice. Plugs were extracted 10 days later and the presence
of vascular endothelial cells determined by immunohisto-
chemistry using anti-CD31 antibodies. Conditioned media
from CSCs attracted significantly more endothelial cells
than the one from H460 or cisplatin-resistant cells
(Fig. 2E and F). These results demonstrated that H460
CSCs promote new vessel formation more efficiently than
the other cell lines.
Metastatic capacity was determined injecting the cells
in the tail vein of immunodeficient mice. Mice were killed
when they showed decreased motility and loss of weight
and the formation of tumors was determined by anatomic
examination of the organs and posterior histological
analyses. H460, CSCs, cisplatin-resistant cells, and a com-
bination of H460 and CSCs in equal proportions were
studied. Most of the inoculated mice developed lung
tumors, as expected from the inoculation protocol used
(Table 2), but also developed metastatic tumors in other
organs, as described for H460 cells [10]. CSCs produced
less tumors that H460 cells (Table 2; 1.4 vs. 1.9), but the
combination of CSCs and H460 cells produced more
metastasis than any of the two cell lines (2.25 tumor/
mouse), indicating that they potentiate each other, in
agreement with the tumorigenic studies.
Cisplatin-resistant cells produced a similar number of
tumors than H460 cells (1.86 tumors/mouse) but a larger
number of bone metastasis (5/14 vs. 1/11). Bilateral bone
metastases were observed in most positive mice. Histolog-
ical analysis of femurs indicated that metastatic precursors
appeared preferably in metaphysis (Fig. 3A). Figure 3A2
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shows some metastatic cells in the bone marrow and next
to growth plate, intimately related to blood vessels. Sam-
ples with more evident traces of metastasis (Fig. 3B–C)
showed complete colonization of the bone marrow and
hypertrophic cartilage tissue in growth plate area. Also
bone tissue integrity was compromised, with destruction
of cortical bone and reactive trabecular bone formation.
Reactive new bone was formed by native bone cells and it
appeared fully infiltrated by tumoral cells (Fig. 3B4).
Large bone lytic areas and extraosseous tumor-mass
formation were observed in the more metastasis-advanced
samples. These data indicate that metastasis mainly starts
in bone marrow of metaphysis area and later affect whole
bone structure (Fig. 3).
Gene expression profiles
The experiments shown above indicated some similarities
between H460 CSCs and cisplatin-resistant cells. To fur-
ther characterize these cell populations, their gene expres-
sion profile was analyzed by DNA microarray
hybridization. Agilent human DNA microarrays were
hybridized to cDNAs derived from H460, CSCs or cis-
platin-resistant cells (GEO code GSE54981). Differences
in gene expression, in comparison to H460 cells, were
identified using a False Discovery Rate (FDR) smaller
than 0.05. A summary of the more relevant genes
detected is shown in Table S2. Genes differentially regu-
lated in CSCs and cisplatin-resistant cells were compared.
A total of 13 genes were commonly upregulated and 13
downregulated in both cells, in comparison to H460 cells
(Fig. S2). Commonly upregulated genes whose function
can be more relevant in cancer-cell biology are shown in
Table 3.
The identification of genes differentially regulated in
CSCs was also approached in a redifferentiation study
where CSCs were cultured under nonadherent conditions
for 10 days and then changed to adherent culture condi-
tions in serum-containing media for 3, 9 or 24 h. Adher-
ent cells appeared under these culture conditions. Gene
expression was compared by DNA microarray hybridiza-
tion (GEO code GSE54712). Differentially-regulated genes
were selected using a FDR < 0.05. The results obtained
are summarized in Table 3 and Table S3.
The differential expression of some of these genes was
validated by quantitative RT-PCR (Fig. S3A). All the
genes analyzed showed a significant induction in CSCs, as
compared to H460 cells, and also a decrease in expression
in differentiated CSCs. Four of the nine genes analyzed
also showed increased expression in cisplatin-resistant
H460 cells. Our group had previously described that
DUSP1 controlled the expression of DUSP6 and proangi-
ogenic genes such as VEGFC [10]. Inhibition of DUSP6
and VEGFC expression correlated with decreased metasta-
sis and angiogenic potential. Furthermore, DUSP1-
depleted H460 cells showed increased sensitive to cisplatin
[6]. Therefore, we have determined the expression of
these genes in the cells obtained in this study. The three
genes were upregulated in H460 cisplatin- resistant and
CSCs (Fig. S3B). In addition, the three genes were also
upregulated in A549 cisplatin-resistant cells and two of
them (DUSP6, VEGFC) in A549 CSCs, further enforcing
the relation between the cisplatin resistance and CSC
potential in NSCLC cell lines.
Figure 2. Isolation and characterization of cells with Cancer Stem Cells (CSC) characteristics from H460 and A549 cells. (A) H460 (A–C) and
A549 (D–F) cells were cultured in defined media, under nonadhesive conditions for 1–10 days. Pictures were taken using a Nikon TS100
microscope. The bar represents a distance of 100 lm. (B) H460 and A549 cells were cultured in 96 well plates at an average density of 48 cell/
plate and the number of clones or spheres present after 10 days of culture was counted. The upper row represents the number of clones
obtained culturing the cells in standard serum-containing media under adherent conditions. The middle row represents the total number of
spheres containing more than four cells obtained culturing the cells in defined media and under nonadherent conditions. The percentage of
spheres (%CSC), as compared to the number of clones, is represented in the lower row of the table. (C) Cisplatin sensitivity. H460 and A549
CSC (H460C, A549C), cisplatin resistant (H460R, A549R), CSCs isolated from H460-resistant cells (H460R-C) or untreated cells (H460, A549) were
incubated with 0–2.5 lg/mL of cisplatin for three days. The number of viable cells was estimated using the MTS reagent at the end of the
treatment. Average values and standard deviations of three independent experiments are represented. (D) Migration of H460 untreated (H460),
cisplatin-resistant (H460R) and CSC (H460C) cells through a matrigel cushion. Fetal Calf Serum was used as chemoatractant. HT1080 and MCF7
cells were used as controls. The lower panel shows microscopic images of the cells that migrated through the matrigel cushion. The quantification
of the number of cells that migrated (ten fields for each cell population) is indicated on the upper panel. Significant differences between H460/
H460R and H460R/H460C cells are indicated by asterisks (*P < 0.05, **P > 0.01). (E and F) Angiogenic capacity of H460 cisplatin-resistant and
CSC cells. Conditioned media obtained for untreated (H460), cisplatin-resistant (H460R) of CSC (H460C) cell lines was embedded in matrigel and
subcutaneously implanted in Nu/Nu mice. Matrigel plugs were extracted 10 days after implantation and the presence of endothelial cells analyzed
by immunohistochemistry using anti-CD31 antibodies. Panel E shows microscopic pictures of the sections where CD31 expression is indicated in
red and DAPI nuclear staining in blue. The lower pictures show the superposition of DAPI staining and CD31 expression. Panel F shows the
quantification of CD31 staining. FGF was used as a positive control and the buffer PBS as a negative control. Significant differences between
H460/H460C and H460R/H460C cells are indicated by asterisks (**P > 0.01).
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Isolation of CSC cells from clinical samples
The presence of CSCs in clinical isolates and the possible
correlation to cisplatin resistance was analyzed. Surgical
samples were obtained from 44 patients diagnosed from
NSCLC that had not received chemotherapy (patients’
characteristics are described in Table S4). Samples were
processed to isolate dispersed cells. One part of the cells
was used to determine cisplatin sensitivity and the other
part cultured under nonadherent conditions in defined
media to observe the possible presence of CSCs. Figure 4
shows the results obtained in the double assay. Samples
able to form spheres are indicated with open circles and
those were no spheres were observed after 30 days in cul-
ture with filled circles. The IC50 for cisplatin obtained
from each sample is represented in the Y-axis.
Previous studies of multiple cell lines in our group
indicated that the average IC50 for cisplatin is 2 lg/mL.
Taking this value as a reference, nine of the patients’ sam-
ples that were sensitive to cisplatin were not able to form
CSC spheres and only one sensitive sample formed them.
These results would indicate that patients with a low
capacity to form CSC spheres are more alike to be sensi-
tive to cisplatin. The statistical test of this hypothesis
using the chi square method gave a significant P-value of
0.028.
Discussion
The biological characteristics and gene expression profiles
of cisplatin resistant and CSCs isolated from two NSCLC
cell lines have been compared. Cisplatin-resistant cells,
isolated after a single treatment with the drug, showed
reduced sensitivity to cisplatin even after prolonged peri-
ods of culture in the absence of the drug. These results
are in agreement with previous studies [18] and indicate
that cisplatin resistance can be induced in patients from
the first treatment and can increase in successive rounds
of treatment.
CSCs were isolated by culture in serum-free media
under nonadherent conditions. This strategy has been
previously used for isolation of CSCs from NSCLC
established [19] and primary cell lines [20, 21]. The iso-
lated populations present CSCs characteristics: self-
renewal, differentiation capacity in the presence of
serum, tumorigenicity, and increased drug resistance.
Putative CSCs were also isolated from 40% of 44 patient
samples analyzed using the same culture conditions. Sev-
eral authors have isolated NSCLC/CSCs from established
cell lines or clinical samples using the expression of CSC
markers [22], dye exclusion [23] or spheroid formation
[19, 24, 21] as criteria. The isolated CSCs differed mark-
edly in the expression of CSC markers [5, 4], in agree-
ment with our data for H460 and A549 CSCs.
Previously isolated CSCs were more resistant to chemo-
therapy or DNA-damaging treatment [19], also in agree-
ment with our data.
The data discussed above indicate that cisplatin resis-
tance and CSC characteristics could be related properties
what prompted us to compare the two independently iso-
lated H460 cell populations. The two populations from
Table 1. Characteristics of the tumors formed after injection in Nu/Nu mice of mixtures, in different proportions, of H460 and H460 CSC
(H460C) cells.
Inoculated cells Tumor distribution
Latency (days) Tumor volume (cm3)% H460 % H460C % H460 % H460C
95 5 ~99  0.094 <1  0.094 20  2.18 0.868  0.42
85 15 90.13  2.42 9.87  2.42 20  4.3 0.748  0.39
75 25 65.42  3.44 34.58  3.44 15  3.42 2.5  0.53
50 50 54.56  10.61 45.44  10.61 23  3.1 0.943  0.43
The proportion of each cell population in the generated tumors, their size and the latency period are indicated.
Table 2. Metastatic tumors formed after intravenous injection of
H460 cells, H460 CSC (H460C), H460 cisplatin-resistant cells (H460R)
or a combination of H460 and H460 CSC (H460 + H460C) cells.
Cell Line ? H460 H460C H460 + H460C H460R
Lung 8 12 4 11
Other organs
Brain – – – –
Salivary gland 1 – – 2
Trachea – 2 1 –
Heart – 1 1 –
Liver 1 – – –
Spleen – – - –
Pancreas 1 1 – –
Intestine – 1 – –
Kidney 3 1 1 1
Genitals 2 – – 1
Bone 1 – 1 5
Other tumors 4 3 1 6
Total number of mice 11 15 4 14
Metastasis/mouse 1.90 1.4 2.25 1.86
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both cell types were less sensitive to cisplatin. In addition,
CSCs derived from H460R cells presented the same sensi-
tivity to the drug than H460 CSCs indicating that the cis-
platin resistance acquired as a consequence of both
treatments was not additional. These data indicate that
H460C and H460R cells could have acquired similar
mechanisms of cisplatin resistance.
H460, H460C, and H460R cell populations generated
tumors when subcutaneously injected in immunodeficient
mice. However, resistant cells and CSCs generated smaller
tumors, with a longer latency period, which could indi-
cate their slower growth. Actually, when mixtures of CSCs
and differentiated cells were inoculated, the proportion of
CSCs decreased in the tumors generated. However, some
proportion of CSCs and differentiated cells showed a high
tumorigenic capacity, producing larger tumors, with
shorter latency period. The proportion of CSCs increased
in these more aggressive tumors. These results indicate
that the presence of CSCs and differentiated cells in the
same tumor might have synergistic effects and result in
the formation of more aggressive tumors, as recently
reported in colorectal cancer [25].
CSCs and cisplatin-resistant cells were able to metasta-
size after intravenous inoculation in immunodeficient
A
A1
A2
B1
B3
C1
C2
B2
B4
B C
Figure 3. Bone metastasis to femur of, vein tail implanted, cisplatin-resistant H460 cells. (A) Femur sample in initial phase of bone metastasis.
(A1) Hematoxylin and Eosin (H&E) staining shows healthy appearance. Immunohistochemistry (IHC) in square-detained area (A2) shows metastatic
cells in metaphysis area and intimately related to blood vessels. (B) Femur sample in advanced metastasis phase. H&E Staining shows (B1)
Metaphysis area with morphological changes in cartilage of growth plate (Arrows), (B2) Hepiphysis area with bone lysis (Arrow heads) in cortical
bone and extramedular tumor mass (Star). IHC in square-detained areas show (B3) Bone marrow fully infiltrated with tumoral cells and (B4)
Human cell-infiltrated reactive bone area. (C) Details of native tissue reaction to advanced metastasis. (C1) Reactive bone formation in epiphysis.
(C2) Hypertrophic cartilage (Arrows) in metaphysis. Both areas are fully infiltrated with tumoral cells (asterisks). Inserted figures in A2, B3, and B4
correspond to negative controls.
Table 3. Summary of the expression levels determined by DNA microarray analyses comparing H460 cells to cisplatin-resistant H460 cells
(H460R), CSC H460 cells (H460C).
Gene Accession number Description
Fold change
(H460R)
Fold change
(H460C)
Fold change
(H460CDif)
EGR1 NM_001964 Early growth response 1 38.08 12.78 –
JUN NM_002228 Proto-oncogene 13.39 13.27 –
PTGS2/COX2 NM_000963 Prostaglandin-endoperoxide synthase 2/Cyclooxygenase 2 4.62 17.84 –
MALAT1 NR_002819 Metastasis-associated lung adenocarcinoma transcript 1 8.59 5.15 –
AKAP12 NM_144497 Kinase (PRKA) anchor protein 12 3.51 7.16 –
ADM NM_001124 Adrenomodullin 5.13 5.6 4.8
CXCR4 NM_001008540 Chemokine (C-X-C motif) receptor 4 – 8.02 7.5
IL1B NM_000576 Interleukin 1, beta – 8.73 5.1
LOXL2 NM_002318 Lysyl oxidase-like 2 – 6.72 8.2
The right column compares CSC cells before and after culture under adherent conditions for 24 h (H460CDif).
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mice. Both cell populations produced a large number of
metastasis in lungs, as H460 cells did, but also in other
organs. CSCs produced a slightly smaller number of
metastasis but a combination of CSCs and unselected cells
produce a larger proportion, in agreement with the results
obtained in the tumorigenic assay. A distinct property of
cisplatin-resistant cells was their increased capacity to
produce bone metastasis.
Lung cancer bone metastases affect 30–40% of patients
with advanced lung cancer and are related to poor prog-
nosis, lower survival time, and skeletal-related events such
as pathological fractures, spinal cord compression, hyper-
calcemia or pain [26]. Common bone metastasis sites are
pelvis, ribs, vertebral bodies, skull, and the long bones
close to the torso [26], being femur a usual location [27]
as observed in this work.
Our data correlates with previous observations for
highly metastatic lung cancer cell lines [28] where a lim-
ited number of metastatic precursors grew within capillar-
ies and extravasation occurred. The subsequent steps were
complete colonization of bone marrow and cortical bone
lysis [28]. Our results (Fig. 3) indicate similar behavior
for cisplatin-resistant H460 cells. We observed reactive
bone formation of murine origin that was fully infiltrated
by human tumoral cells.
CSCs and cisplatin-resistant cells also differed in the
higher invasive capacity of cisplatin-resistant cells. CSCs,
however, showed a higher capacity to induce angiogenesis
in immunodeficient mice, which could potentiate tumor
growth.
Gene expression analyses also indicated a close relation-
ship between CSCs and cisplatin-resistant H460 cells.
Thirteen genes were commonly upregulated, and 13
downregulated, in both cell populations. The differential
expression of six of the commonly upregulated genes was
confirmed by quantitative RT-PCR. Three of these genes,
JUN, EGR1, and AKAP12, are involved in the control of
cell proliferation and cancer progression [29]. AKAP12
and EGR1expression have been associated with cisplatin
resistance [30, 31]. COX2 (PTGS2) is overexpressed in
the first steps of lung carcinogenesis and its overexpres-
sion has been considered of bad prognosis [32]. COX2
has also been associated with drug resistance in NSCLC
[33]. MALAT1 codes for a large noncoding RNA and is
expressed in tumoral processes, including lung adenocar-
cinoma [34]. The adrenomedullin peptide (ADM) is con-
sidered a proto-oncogene that plays multiple roles in
cancer [35]. ADM induces the expression of early
response genes, such as JUN and EGR1 [36], angiogenesis
and lymphangiogenesis [37]. In addition, both COX2 and
ADM mediate carcinogenesis produced by cigarette
smoke [38, 39].
The expression of other genes is specifically regulated
in CSCs. Some upregulated genes are involved in cytokine
activity, such as IL1A, IL1B, CXCL14, CCL20, AREG, IN-
HBA, and CXCR4 and are repressed upon CSC differenti-
ation. Overexpression of growth factors by CSCs is in
agreement with the observation that H460 CSCs prolifer-
ate in the absence of added growth factors. Levina et al.
[18] also described that CSCs obtained from H460 cells
expressed a large number of growth factors and receptors
when implanted in SCID mice. The specific growth fac-
tors identified in this study do not completely coincide
with those found overexpressed in the present article,
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Figure 4. Comparison of cisplatin sensitivity and the presence of
sphere-forming cells in surgical samples of NSCLC patients. Surgical
samples of NSCLC patients that had not received any pharmacological
treatment were disaggregated. Half of the cells obtained were used
to analyze cisplatin sensitivity and their IC50 determined. The other
half was cultured in defined media under nonadherent conditions and
the presence of cell spheres determined after 30 days in culture. The
IC50 values obtained are represented for each patient. Patient
samples that contained sphere-forming cells are indicated with open
circles (CSC) and those that did not with close circles (NO CSC). A
IC50 value of 2 lg/mL was considered the limit between cisplatin
sensitive and resistant cells. Bar, median value of each group.
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which could be due to the very different conditions used:
Xenografts versus cell culture.
Among these genes IL1B and CXCR4 play an important
role in angiogenesis [40], in agreement with the increased
angiogenic capacity of CSCs. Previous studies also
reported upregulation of CXCR4 in lung CSCs [18] and
suggested that this gene plays a role in metastasis and cis-
platin resistance [22, 41]. This molecule has been sug-
gested as a potential target for treatment of metastatic
lung cancer [42]. LOXL2, upregulated in CSCs, is involved
in cell proliferation, metastasis, and angiogenesis [43], and
TMEM158 has been related to cisplatin resistance [44].
The genes specifically underexpressed in CSCs are sig-
nificantly enriched in IGF binding (IGFBP3, 6, 7, NOV,
CRIM1) and cell adhesion (ANTXD1, ITGB5, ITGBL1,
ITGA7, CDH11, CDH13). CDH13 underexpression was
related to tumor invasion and cell migration. Underex-
pressed endopeptidase inhibitors (SERPIN-B11, -D1) that
impair extracellular matrix degradation might result in
tumor invasion and metastasis [45].
Resistant cells show significant overexpression of genes
involved in the response to chemical stimuli such as five
metalothionein-coding genes that confer cisplatin resis-
tance due to their antiapoptotic activity and their capacity
to interact with cisplatin [46]. In addition, glutation per-
oxidase 3 (GPX3) has been involved in drug resistance
[47].
H460 cisplatin-resistant and CSCs expressed higher lev-
els of DUSP1, DUSP6, and VEGFC genes, previously
involved in cisplatin resistance and tumorigenicity [10].
Cisplatin-resistant A549 cells also expressed increased lev-
els of these genes while A549 CSCs expressed increased
levels of DUSP6 and VEGFC but lower levels of DUSP1.
CSCs from H460 and A549 expressed increased levels
of epithelial markers and one mesenchymal marker but
decreased levels of a second mesenchymal protein. These
changes were reverted upon CSC differentiation. These
results are in agreement with recent reports showing that
CSC populations present both epithelial and mesenchymal
characteristics [48, 49].
In summary, H460 CSC and cisplatin-resistant cells
have in common their decreased sensitivity to cisplatin,
that is not additive in H460R-derived CSCs. Both cell
types produce smaller tumors with larger latency periods
than untreated cells, indicative of smaller proliferation
capacity. A third common characteristic is the similar reg-
ulation in the expression of a significant number of genes,
Both cell types also differ in some of their properties as
are the increased angiogenic capacity of H460C and the
larger invasive capacity and production of bone metastasis
of H460R cells.
The possible clinical implication of the correlation
observed between cisplatin resistance and CSCs has
been approached. Forty-four surgical samples of
untreated NSCLC patients were analyzed for their sensi-
tivity to cisplatin and for the presence of CSCs. Ten
samples were considered sensitive to cisplatin
(IC50 < 2 lg/mL) and only one of them was able to
grow as spheres in conditioned media. In contrast, 17
of 34 samples resistant to cisplatin generated spheres.
Although the absence of CSCs in some samples could
be due to the heterogeneity of the tumors and the
study of a larger number of patients is required to
drive definitive conclusions, statistical analyses of the
data obtained indicate that patients who do not host
cells able to grow as spheres are more likely to respond
to cisplatin treatment (P = 0.028).
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